In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence. Zar FA. Ann Intern Med 2025 Apr 1. doi: 10.7326/ANNALS-25-00552.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zar FA. In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence. Ann Intern Med 2025 Apr 1. doi: 10.7326/ANNALS-25-00552.
PMID: 40163885